54 results on '"Wolf, Douglas A."'
Search Results
2. S1027 Impact of Prior Biologic Exposure on the Durability of 3-Year Continuous Ozanimod Treatment
3. S906 Efficacy and Durability of Ozanimod by Baseline Endoscopic Disease Activity in Advanced Therapy–Naive Ulcerative Colitis Patients Suboptimally Controlled on Conventional Therapies
4. S1067 Impact of Prior Biologic/Janus Kinase Inhibitor Therapy on the Efficacy of Etrasimod: Subgroup Analysis From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials
5. S1035 Analysis of Baseline Characteristics Associated With Clinical Response to Ustekinumab IV Re-Induction Strategy in Patients With Crohn’s Disease in the POWER Trial
6. S1134 Association of Nonswitched Memory B-Cell (MBC) Levels With Ozanimod (OZA) Efficacy in Patients (Pts) With Moderately to Severely Active Crohn’s Disease (CD): Results From the Phase 2 STEPSTONE Study
7. S911 Long-Term Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
8. S732 Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Moderate orSevere Endoscopic Disease Activity at Baseline: A Post Hoc Analysis of the Phase 3 True North Study
9. S734 Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12
10. P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study
11. P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
12. S926 Effects of Immune Modifying Therapies on Antibody Responses Following SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease
13. S853 Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies
14. S846 Endoscopic Healing Index Is a Good Surrogate Marker of Intestinal Ulcerations in Patients With Crohn’s Disease
15. S950 Symptomology Following SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease Relative to Healthcare Workers
16. S899 Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need From CorEvitas’ Inflammatory Bowel Disease Registry
17. S900 Real World Treatment (Tx) Patterns and Healthcare Costs Among U.S. Commercially Insured Adults Initiating Biologics for Ulcerative Colitis (UC)
18. S742 A National Cohort of IBD Patients Exhibit Strong COVID-19 Safety Practice Beliefs
19. S693 Impact of Prior Biologic Exposure on Patient Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study
20. S867 Ozanimod for Moderate-to-Severe Ulcerative Colitis: Results From the North American Population During Induction and Maintenance in the Phase 3 True North Study
21. P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
22. P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study
23. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate
24. 634 Transitioning From Vedolizumab IV to Vedolizumab SC in Patients With Ulcerative Colitis: Results From the VISIBLE Program
25. Safety and Efficacy of Long-term Treatment With Ozanimod: An Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis - TOUCHSTONE Extension 2-Year Follow-up
26. Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohnʼs Disease
27. Ozanimod, an Oral S1P Receptor Modulator, Is Effective and Well-Tolerated in the Long-Term Treatment of Moderate to Severe Ulcerative Colitis
28. Endoscopic Healing in Induction and Maintenance with Ustekinumab in the Phase 3 UNITI Crohnʼs Disease Program: 2016 ACG Presidential Poster Award
29. A Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study
30. Safety Profile of Extraintestinal Manifestations of Crohnʼs Disease During Treatment With Certolizumab Pegol
31. Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
32. Disease Activity as a Predictor of Long-Term Outcomes of Treatment With Certolizumab Pegol for Active Crohn’s Disease: An Analysis of the PRECiSE 3 Study
33. Improvement of C-Reactive Protein in Certolizumab Pegol Responders, but Not in Non-Responders in Crohn’s Disease
34. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Results From Safety Surveillance
35. Clinical Benefit of Adalimumab Dose Adjustment for Patients With Moderately to Severely Active Crohn’s Disease in EXTEND
36. Mucosal Healing in Ulcerative Colitis Patients with Week 8 Response to Adalimumab: Subanalysis of ULTRA 2
37. Reduced Steroid Usage in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2
38. Clinical Experience with Measurement of Serum Infliximab and Antibodies to Infliximab Using a New Homogenous Mobility Shift Assay: Results of a Multi-center Observational Study
39. Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
40. Influence of Trough Serum Drug Level and Immunogenicity on the Lack of Response to Adalimumab Therapy in IBD Patients Presidential Poster
41. Rate of and Response to Dose Escalation in Patients Treated With Adalimumab for Moderately to Severely Active Ulcerative Colitis: Subanalysis of ULTRA 2
42. Benefit-Risk Assessment of Adalimumab as Maintenance Treatment for Ulcerative Colitis: NEAR Analysis of Week 8 Responders in ULTRA 2
43. Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol
44. A Serogenetic Test Accurately Predicts the Probability of Complicated Crohnʼs Disease
45. Patient Self-assessed HBI Correlates Highly with Physician-Assessed HBI in the Secure Registry
46. Efficacy of Certolizumab Pegol in Crohnʼs Disease Patients with Secondary Failure to Infliximab Is Not Affected by Concomitant Medications
47. Improvement in Work Productivity and Daily Activities by Certolizumab Pegol in Crohnʼs Disease Patients with Prior Loss of Response or Intolerance to Infliximab
48. Regain of Response and Remission by Dose Adjustment in Patients with Crohnʼs Disease Who Responded to Certolizumab Pegol: Results from the WELCOME Study
49. Efficacy of Certolizumab Pegol is Not Affected by Baseline Anti-infliximab Antibody Status in Patients with Crohnʼs Disease with Secondary Infliximab Failure
50. Certolizumab Pegol Treatment Impacts Hospitalizations and Surgeries in Crohnʼs Disease Patients with Prior Failure to Infliximab: Results From WELCOME Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.